4phu
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | ''' | + | ==Crystal structure of Human GPR40 bound to allosteric agonist TAK-875== |
| - | + | <StructureSection load='4phu' size='340' side='right' caption='[[4phu]], [[Resolution|resolution]] 2.33Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[4phu]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHU FirstGlance]. <br> | |
| - | + | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2YB:[(3S)-6-({2,6-DIMETHYL-4-[3-(METHYLSULFONYL)PROPOXY]BIPHENYL-3-YL}METHOXY)-2,3-DIHYDRO-1-BENZOFURAN-3-YL]ACETIC+ACID'>2YB</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene><br> | |
| - | + | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Lysozyme Lysozyme], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.1.17 3.2.1.17] </span></td></tr> | |
| - | + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phu OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4phu RCSB], [http://www.ebi.ac.uk/pdbsum/4phu PDBsum]</span></td></tr> | |
| + | <table> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Lysozyme]] | ||
| + | [[Category: Aertgeerts, K.]] | ||
| + | [[Category: Gruswitz, F.]] | ||
| + | [[Category: Hirozane, Y.]] | ||
| + | [[Category: Ivetac, A.]] | ||
| + | [[Category: Jennings, A.]] | ||
| + | [[Category: Kefala, G.]] | ||
| + | [[Category: Lane, W.]] | ||
| + | [[Category: Nguyen, J.]] | ||
| + | [[Category: Okada, K.]] | ||
| + | [[Category: Snell, G.]] | ||
| + | [[Category: Srivastava, A.]] | ||
| + | [[Category: Yano, J K.]] | ||
| + | [[Category: Class some]] | ||
| + | [[Category: Fasiglifam]] | ||
| + | [[Category: Fatty acid binding protein]] | ||
| + | [[Category: Fatty acid binding protein-hydrolase complex]] | ||
| + | [[Category: G-protein coupled receptor]] | ||
| + | [[Category: Gpr40]] | ||
| + | [[Category: Tak-875]] | ||
| + | [[Category: Type ii diabetes]] | ||
Revision as of 10:31, 16 July 2014
Crystal structure of Human GPR40 bound to allosteric agonist TAK-875
| |||||||||||
Categories: Lysozyme | Aertgeerts, K. | Gruswitz, F. | Hirozane, Y. | Ivetac, A. | Jennings, A. | Kefala, G. | Lane, W. | Nguyen, J. | Okada, K. | Snell, G. | Srivastava, A. | Yano, J K. | Class some | Fasiglifam | Fatty acid binding protein | Fatty acid binding protein-hydrolase complex | G-protein coupled receptor | Gpr40 | Tak-875 | Type ii diabetes
